Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efineptakin alfa - Genexine

Drug Profile

Efineptakin alfa - Genexine

Alternative Names: Efineptakin alfa NT-I7; GX I7; HyLeukin; HyLeukin-7™; IL-7 Hybrid Fc; IL-7-hyFc; Interleukin-7-hybrid-Fc-recombinant-protein; NT I7; Recombinant human IL-7-hyFc; Recombinant human interleukin-7 hybrid Fc; rhIL-7 - Genexine/I-MAB Biopharma; rhIL-7-hyFc; TJ 107

Latest Information Update: 10 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genexine
  • Developer Bristol-Myers Squibb; Fred Hutchinson Cancer Research Center; Genexine; I-MAB Biopharma; Merck & Co; National Cancer Institute (USA); National Institute of Neurological Disorders and Stroke; NeoImmuneTech; PT Kalbe Genexine Biologics; Roche; Yonsei University
  • Class Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Radioprotectives; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Interleukin 7 replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome; Progressive multifocal leukoencephalopathy; Glioblastoma; Pancreatic cancer; Idiopathic CD4-positive T-lymphocytopenia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Adenocarcinoma; COVID 2019 infections; Glioblastoma; Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
  • Phase I/II Pancreatic cancer; Skin cancer; Small cell lung cancer; Solid tumours
  • Phase I Anal cancer; Biliary cancer; Cervical cancer; Diffuse large B cell lymphoma; Kaposi's sarcoma; Ovarian cancer; Progressive multifocal leukoencephalopathy
  • Preclinical Acute radiation syndrome
  • No development reported Bladder cancer; Breast cancer; Cervical intraepithelial neoplasia; Colorectal cancer; Human papillomavirus infections; Idiopathic CD4-positive T-lymphocytopenia; Lymphoma

Most Recent Events

  • 04 Jun 2024 Efineptakin alfa - Genexine receives Orphan Drug status for Acute radiation syndrome in Europe
  • 04 Jun 2024 NeoImmuneTech plans a clinical trial for Hematologic malignancies, Solid tumours and Autoimmune disorders
  • 03 Jun 2024 Updated efficacy data from a phase IIa trial in solid tumour released by NeoImmuneTech
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top